Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 5/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27692795 | 1.00 | RIPK1 (0.50) | RIPK1LMNAKDM4EL3MBTL1AOC3 | |
| SCHEMBL20991906 | 0.90 | RIPK1 (0.48) | RIPK1LMNAKDM4EL3MBTL1AOC3 | |
| SCHEMBL18893532 | 0.90 | RIPK1 (0.48) | RIPK1LMNAKDM4EL3MBTL1AOC3 | |
| SCHEMBL5629157 | 0.89 | LMNA (0.41) | RIPK1LMNAKDM4EL3MBTL1HTR1A | |
| SCHEMBL9464565 | 0.80 | AOC3 (0.44) | KDM4EAOC3HTR1A | |
| SCHEMBL5185803 | 0.79 | RIPK1 (0.64) | RIPK1LMNAKDM4EL3MBTL1AOC3 | |
| SCHEMBL3081755 | 0.79 | RIPK1 (0.64) | RIPK1LMNAKDM4EL3MBTL1AOC3 | |
| SCHEMBL2939704 | 0.79 | RIPK1 (0.50) | RIPK1LMNAKDM4EL3MBTL1AOC3 | |
| SCHEMBL610027 | 0.78 | LMNA (0.52) | RIPK1LMNAKDM4EL3MBTL1AOC3 | |
| SCHEMBL15195448 | 0.78 | LMNA (0.52) | RIPK1LMNAKDM4EL3MBTL1AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11339174-B2 | γ-spiroketal-γ-lactones and pharmaceutical composition containing same and process for preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2022-05-24 | — | — | US | claimed |
| US-20210198273-A1 | GAMMA-SPIROKETAL-GAMMA-LACTONES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AND PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2021-07-01 | — | — | US | claimed |
| EP-3619214-A1 | GAMMA-SPIROKETAL-GAMMA-LACTONES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AND PROCESS FOR PREPARATION THEREOF | Council of Scientific and Industrial Research (IN) | 2020-03-11 | — | — | EP | claimed |
| WO-2018203346-A1 | γ-SPIROKETAL- γ –LACTONES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AND PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2018-11-08 | — | — | WO | claimed |
| US-11339174-B2 | γ-spiroketal-γ-lactones and pharmaceutical composition containing same and process for preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2022-05-24 | — | — | US | disclosed |
| US-20210198273-A1 | GAMMA-SPIROKETAL-GAMMA-LACTONES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AND PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2021-07-01 | — | — | US | disclosed |
| EP-3619214-A1 | GAMMA-SPIROKETAL-GAMMA-LACTONES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AND PROCESS FOR PREPARATION THEREOF | Council of Scientific and Industrial Research (IN) | 2020-03-11 | — | — | EP | disclosed |
| WO-2018203346-A1 | γ-SPIROKETAL- γ –LACTONES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AND PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2018-11-08 | — | — | WO | disclosed |
| EP-1810967-B1 | Processes and intermediates for the preparations of prostaglandins | CHIROGATE INT INC (TW) | 2014-07-30 | — | — | EP | disclosed |
| US-8030514-B2 | Processes and intermediates for the preparations of prostaglandins | CHIROGATE INTERNATIONAL INC. (TW) | 2011-10-04 | — | — | US | disclosed |
| US-20090299088-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF PROSTAGLANDINS | CHIROGLATE INTERNATIONAL INC. | 2009-12-03 | — | — | US | disclosed |
| US-7626024-B2 | Processes and intermediates for the preparations of prostaglandins | Irogate International Inc. (CN) | 2009-12-01 | — | — | US | disclosed |
| US-7582779-B2 | Processes and intermediates for the preparations of prostaglandins | CHIROGATE INTERNATIONAL INC. (TW) | 2009-09-01 | — | — | US | disclosed |
| US-7511168-B2 | Processes and intermediates for the preparations of prostaglandins | Wei, Shih-Yi (TW) | 2009-03-31 | — | — | US | disclosed |
| US-20080039637-A1 | Processes and intermediates for the preparations of prostaglandins | CHIROGATE INTERNATIONAL INC. | 2008-02-14 | — | — | US | disclosed |
| US-20080039627-A1 | Processes and intermediates for the preparations of prostaglandins | CHIROGATE INTERNATIONAL INC. | 2008-02-14 | — | — | US | disclosed |
| EP-1810967-A1 | Processes and intermediates for the preparations of prostaglandins | Chirogate International Inc. (TW) | 2007-07-25 | — | — | EP | disclosed |
| US-20070167641-A1 | Processes and intermediates for the preparations of prostaglandins | CHIROGATE INTERNATIONAL INC. | 2007-07-19 | — | — | US | disclosed |
| US-4877779-A | CALCIUM CHANNEL BLOCKERS; TREATMENT OF IRRITABLE BOWEL SYNDROME | MARION LABORATORIES, INC. (US) | 1989-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090299088-A1 | PROCESSES AND INTERMEDIATES FOR THE PREPARATIONS OF PROSTAGLANDINS | PTGES, PTGER1, PTGIS | RIPK1 4234/4885LMNA 1678/4885KDM4E 2828/4885 |
| US-20070167641-A1 | Processes and intermediates for the preparations of prostaglandins | PTGES, PTGER1, PTGIS | RIPK1 4234/4885LMNA 1678/4885KDM4E 2828/4885 |
| US-20080039637-A1 | Processes and intermediates for the preparations of prostaglandins | PTGES, PTGER1, PTGIS | RIPK1 4234/4885LMNA 1678/4885KDM4E 2828/4885 |
| US-11339174-B2 | γ-spiroketal-γ-lactones and pharmaceutical composition containing same and process for preparation thereof | HSD17B7, PKD1, CYP17A1 | RIPK1 3460/4885LMNA 1079/4885KDM4E 3002/4885 |
| US-20080039627-A1 | Processes and intermediates for the preparations of prostaglandins | PTGES, PTGER1, PTGIS | RIPK1 4234/4885LMNA 1678/4885KDM4E 2828/4885 |
| US-20210198273-A1 | GAMMA-SPIROKETAL-GAMMA-LACTONES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AND PROCESS FOR PREPARATION THEREOF | HSD17B7, PKD1, CYP17A1 | RIPK1 3628/4885LMNA 1031/4885KDM4E 2967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.